{"url_path":"/sec/sion/8-k/2026-05-12/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/2036042/0001628280-26-033870-index.html","accession_number":"0001628280-26-033870","cik":"0002036042","ticker":"SION","issuer_name":"Sionna Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2036042/0001628280-26-033870-index.html","primary_entity_key":"0002036042","primary_entity_name":"Sionna Therapeutics, Inc."},"word_count":136,"has_tables":true,"body_markdown":"Item 2.02    Results of Operations and Financial Condition.\n\nOn May 12, 2026, Sionna Therapeutics, Inc. issued a press release announcing its financial results and business highlights for the three months ended March 31, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information set forth under this Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing."}